Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Pharmacol ; 60(6): 1383-91, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11723246

ABSTRACT

S23906-1 is a diester derivative of 1,2-dihydrobenzo[b]acronycine with an unknown mechanism of action. This cytotoxic compound was 20-fold more potent than acronycine in inhibiting the proliferation of six tumor cell lines. Using a clonogenic assay of cell survival, the HT29 human colon carcinoma cell line was 100-fold more sensitive to S23906-1 than acronycine. Cell cycle analysis, by flow cytometry, showed that S23906-1 induced a partially reversible arrest of HT29 cells in G2+M at 1 microM and below and an irreversible arrest in S phase at 2.5 microM and above. These cell cycle effects were followed by cell death through apoptosis, quantified by annexin-V labeling. Inhibition of DNA synthesis was observed by complete prevention of bromodeoxyuridine (BrdU) incorporation after only 4 h of incubation with 5 microM S23906-1. Interestingly, under the same experimental conditions, a significant increase of cyclin E protein level was observed without any modification of cyclins D1, D2, D3, or A. This overexpressed cyclin E protein was not complexed with Cdk2, as shown by western blotting for Cdk2 in immunoprecipitates of cyclin E. Similar inhibition of BrdU incorporation and elevation of cyclin E protein were observed after treatment with cytosine arabinoside, which reversibly inhibited progression into S phase, but not after DNA damage induced by cisplatin. S23906-1 thus has a novel mechanism of action. A cell line resistant to S23906-1 showed that overexpression of cyclin E was implicated in the novel cytotoxic activity of this compound.


Subject(s)
Acronine/analogs & derivatives , Acronine/pharmacology , Apoptosis , Cyclin E/biosynthesis , DNA/drug effects , S Phase/drug effects , Antineoplastic Agents/pharmacology , Bromodeoxyuridine/metabolism , Bromodeoxyuridine/pharmacology , Cell Division/drug effects , DNA/biosynthesis , Flow Cytometry , HT29 Cells , Humans , Tumor Cells, Cultured
2.
Bioorg Med Chem Lett ; 11(16): 2205-8, 2001 Aug 20.
Article in English | MEDLINE | ID: mdl-11514171

ABSTRACT

Structure-activity relationship studies of a new series of tripentones (thieno[2,3-b]pyrrolizin-8-ones), led us to prepare several derivatives with antiproliferative activities. The most promising 3-(3-hydroxy-4-methoxyphenyl)thieno[2,3-b]pyrrolizin-8-one 20 (leukemia L1210, IC(50)=15 nM) was shown to be a potent inhibitor of tubulin polymerization.


Subject(s)
Antineoplastic Agents/chemical synthesis , Pyrrolizidine Alkaloids/chemical synthesis , Animals , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Drug Screening Assays, Antitumor , Humans , Leukemia L1210/pathology , Mice , Pyrrolizidine Alkaloids/chemistry , Pyrrolizidine Alkaloids/pharmacology , Structure-Activity Relationship , Tubulin Modulators , Tumor Cells, Cultured
3.
Bioorg Med Chem ; 9(2): 357-65, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11249128

ABSTRACT

Glycosylated indolocarbazoles related to the antibiotic rebeccamycin represent an important series of antitumor drugs. In the course of structure-activity relationship studies, we report the synthesis of two new derivatives containing an indolo[2,3-c]carbazole chromophore instead of the conventional indolo[2,3-a]carbazole unit found in the natural metabolites. The N-methylated compound 8 containing one glucose residue behaves as a typical DNA intercalating agent, as judged from circular and electric linear dichroism measurements with purified DNA. In contrast, the bis-glycosylated derivative 7 containing a glucose residue on each indole nitrogen has lost its capacity to form stable complexes with DNA. DNA relaxation experiments reveal that the two drugs 7 and 8 have weak effects on human DNA topoisomerase I. The modified conformation of the indolocarbazole chromophore is detrimental to the stabilization of topoisomerase I-DNA complexes. The lack of potent topoisomerase I inhibition leads to decreased cytotoxicity but, however, we observed that the DNA-intercalating mono-glycosyl derivative 8 is about 5 times more cytoxic than the bis-glycosyl analogue 7. The study suggests that the naturally-occurring indolo[2,3-a]carbazole skeleton should be preserved to maintain the topoisomerase I inhibitory and cytotoxic activities.


Subject(s)
Aminoglycosides , Anti-Bacterial Agents/pharmacology , Antineoplastic Agents/chemical synthesis , Indoles , Animals , Anti-Bacterial Agents/chemical synthesis , Anti-Bacterial Agents/metabolism , Antineoplastic Agents/metabolism , Antineoplastic Agents/pharmacology , Carbazoles/chemistry , Cattle , Cell Cycle/drug effects , Cell Division/drug effects , Circular Dichroism , DNA/metabolism , DNA Topoisomerases, Type I/metabolism , Glycosylation , Humans , Intercalating Agents/chemical synthesis , Intercalating Agents/metabolism , Intercalating Agents/pharmacology , Leukemia/pathology , Mice , Polydeoxyribonucleotides/metabolism , Structure-Activity Relationship , Topoisomerase I Inhibitors , Tumor Cells, Cultured/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...